Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Afinitor | Everolimus | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex | Do not list | Complete | ||
| Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
| Intelence | Etravirine | HIV | List with clinical criteria and/or conditions | Complete | ||
| Velsipity | etrasimod | Ulcerative colitis | Active | |||
| Hemgenix | etranacogene dezaparvovec | Hemophilia B | Reimburse with clinical criteria and/or conditions | Active | ||
| NuvaRing | Etonogestrel/ethinyl estradiol | Contraceptive, ring | List with clinical criteria and/or conditions | Complete | ||
| Nexplanon | etonogestrel | Prevention of pregnancy | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| Erelzi | Etanercept | Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 16, 2024